Immune-suppressive properties of the tumor microenvironment

Cancer Immunology, Immunotherapy

Volumn 62, Issue 7, 2013, Pages 1137-1148

  Becker, Jürgen C ^a   Andersen, Mads Hald ^b   Schrama, David ^a   Thor Straten, Per ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

A disintegrin and metalloproteinase (ADAM); Adenosine; Arginase; Hypoxia; Indoleamine 2,3 dioxygenase (IDO); Natural killer group 2 member D (NKG2D) ligands

Indexed keywords

ADAM PROTEIN; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ARGINASE; GELATINASE A; INDOLEAMINE 2,3 DIOXYGENASE; MATRIX METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; PROGRAMMED DEATH 1 RECEPTOR; SCLEROPROTEIN; TRYPTOPHAN 2,3 DIOXYGENASE;

BLADDER CANCER; CANCER CELL; CANCER INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME REPRESSION; GLIOBLASTOMA; HUMAN; HYPOXIA; IMMUNOMODULATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH2 CELL; TUMOR MICROENVIRONMENT;

ARGINASE; CELL HYPOXIA; EXTRACELLULAR MATRIX; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; STROMAL CELLS; TRYPTOPHAN OXYGENASE; TUMOR MICROENVIRONMENT;

EID: 84879515584     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1434-6     Document Type: Review

References (84)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674. doi: 10.1016/j.cell.2011.02.013
2. Pietras K, Östman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324-1331. doi: 10.1016/j.yexcr.2010.02.045
3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867. doi: 10.1038/nature01322
4. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411-423. doi: 10.1016/j.ccr.2005.04.014
5. Colotta F, Allavena P, Sica A, et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081. doi: 10.1093/carcin/bgp127
6. Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18:884-901. doi: 10.1016/j.devcel.2010.05.012
7. Rosenberg SA (2012) Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 4:127ps8. doi: 10.1126/scitranslmed.3003634
8. Kerkar SP, Restifo NP (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72:3125-3130. doi: 10.1158/0008-5472.CAN-11-4094
9. Bronte V, Mocellin S (2009) Suppressive influences in the immune response to cancer. J Immunother 32:1-11. doi: 10.1097/CJI.0b013e3181837276
10. Andersen MH, Schrama D, thor Straten P, Becker JC (2006) PS-JID-5700001.indd. J Invest Dermatol 126:32-41. doi: 10.1038/sj.jid.5700001
11. Hajishengallis G, Chavakis T (2013) Endogenous modulators of inflammatory cell recruitment. Trends Immunol 34:1-6. doi: 10.1016/j.it.2012.08.003
12. Brennan PJ, Brigl M, Brenner MB (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13:101-117. doi: 10.1038/nri3369
13. Mantovani A (2009) The yin-yang of tumor-associated neutrophils. Cancer Cell 16:173-174. doi: 10.1016/j.ccr.2009.08.014
14. Matzinger P, Kamala T (2011) Tissue-based class control: the other side of tolerance. Nat Rev Immunol 11:221-230. doi: 10.1038/nri2940
15. Hofmann UB, Houben R, Bröcker E-B, Becker JC (2005) Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87:307-314. doi: 10.1016/j.biochi.2005.01.013
16. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gen Dev 14:163-176
17. Sheu BC, Hsu SM, Ho HN, et al (2001) A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61:237-242
18. Boutet P, Agüera-González S, Atkinson S, et al (2009) Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182:49-53
19. Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32:380-387. doi: 10.1016/j.it.2011.05.005
20. Godefroy E, Manches O, Dréno B, et al (2011) Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory TH2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell 19:333-346. doi: 10.1016/j.ccr.2011.01.037
21. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17:6985-6991. doi: 10.1158/1078-0432.CCR-11-1331
22. Platten M, Wick W, Van den Eynde BJ (2012) Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72:5435-5440. doi: 10.1158/0008-5472.CAN-12-0569
23. Zou W, Restifo NP (2010) TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10:248-256. doi: 10.1038/nri2742
24. Weinlich G, Murr C, Richardsen L, et al (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214:8-14. doi: 10.1159/000096906
25. Smith C, Chang MY, Parker KH, et al (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2:722-735. doi: 10.1158/2159-8290.CD-12-0014
26. Andersen MH (2012) The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. Cancer Immunol Immunother 61:1289-1297. doi: 10.1007/s00262-012-1234-4
27. Pilotte L, Larrieu P, Stroobant V, et al (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Nat Acad Sci 109:2497-2502. doi: 10.1073/pnas.1113873109
28. Nowak EC, de Vries VC, Wasiuk A, et al (2012) Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med 209:2127-2135. doi: 10.1084/jem.20120408
29. Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641-654. doi: 10.1038/nri1668
30. Rundhaug JE, Simper MS, Surh I, Fischer SM (2011) The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 30:465-480. doi: 10.1007/s10555-011-9317-9
31. Chouaib S, Messai Y, Couve S, et al (2012) Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 3:21. doi: 10.3389/fimmu.2012.00021
32. Wink DA, Hines HB, Cheng RYS, et al (2011) Nitric oxide and redox mechanisms in the immune response. J Leuk Biol 89:873-891. doi: 10.1189/jlb.1010550
33. Jayaraman P, Parikh F, Lopez-Rivera E, et al (2012) Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 188:5365-5376. doi: 10.4049/jimmunol.1103553
34. Singer K, Gottfried E, Kreutz M, Mackensen A (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60:425-431. doi: 10.1007/s00262-010-0967-1
35. Hirschhaeuser F, Sattler UGA, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71:6921-6925. doi: 10.1158/0008-5472.CAN-11-1457
36. Shime H, Yabu M, Akazawa T, et al (2008) Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 180:7175-7183
37. Cham CM, Gajewski TF (2005) Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol 174:4670-4677
38. Mandapathil M, Szczepanski MJ, Szajnik M, et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285:27571-27580. doi: 10.1074/jbc.M110.127100
39. Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:5346-5358. doi: 10.1038/onc.2010.292
40. Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759-770. doi: 10.1038/nrd2638
41. Waickman AT, Alme A, Senaldi L, et al (2012) Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 61:917-926. doi: 10.1007/s00262-011-1155-7
42. Su Y, Jackson EK, Gorelik E (2011) Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 60:111-122. doi: 10.1007/s00262-010-0924-z
43. Häusler SFM, Montalbán del Barrio I, Strohschein J, et al (2011) Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 60:1405-1418. doi: 10.1007/s00262-011-1040-4
44. Kryczek I, Wu K, Zhao E, et al (2011) IL-17+ regulatory T Cells in the microenvironments of chronic inflammation and cancer. J Immunol 186:4388-4395. doi: 10.4049/jimmunol.1003251
45. Ryzhov S, Novitskiy SV, Goldstein AE, et al (2011) Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+ Gr1+ Cells. J Immunol 187:6120-6129. doi: 10.4049/jimmunol.1101225
46. Beavis PA, Stagg J, Darcy PK, Smyth MJ (2012) CD73: a potent suppressor of antitumor immune responses. Trends Immunol 33:231-237. doi: 10.1016/j.it.2012.02.009
47. Jin D, Fan J, Wang L, et al (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70:2245-2255. doi: 10.1158/0008-5472.CAN-09-3109
48. Garber K (2011) Beyond ipilimumab: new approaches target the immunological synapse. J Nat Cancer Inst 103:1079-1082. doi: 10.1093/jnci/djr281
49. Cameron F, Whiteside G, Perry C (2011) Ipilimumab: first global approval. Drugs 71:1093-1104. doi: 10.2165/11594010-000000000-00000
50. Callahan MK, Wolchok JD, Allison JP (2010) Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37:473-484. doi: 10.1053/j.seminoncol.2010.09.001
51. Robert C, Thomas L, Bondarenko I, et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526. doi: 10.1056/NEJMoa1104621
52. Reck M, Bondarenko I, Luft A, et al (2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small- cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:75-83. doi: 10.1093/annonc/mds213
53. Di Giacomo AM, Ascierto PA, Pilla L, et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879-886. doi: 10.1016/S1470-2045(12) 70324-8
54. Postow MA, Callahan MK, Barker CA, et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925-931. doi: 10.1056/NEJMoa1112824
55. Santegoets SJAM, Stam AGM, Lougheed SM, et al (2012) T cell profiling reveals high CD4(+)CTLA-4 (+) T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. doi: 10.1007/s00262-012-1330-5
56. Hodis R, Watson IR, Kryukov GV, et al (2012) A landscape of driver mutations in melanoma. Cell 150:251-263. doi: 10.1016/j.cell.2012.06.024
57. Downey SG, Klapper JA, Smith FO, et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681-6688. doi: 10.1158/1078-0432.CCR-07-0187
58. Liakou CI, Kamat A, Tang DN, et al (2008) CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Nat Acad Sci 105:14987-14992. doi: 10.1073/pnas.0806075105
59. Ji R-R, Chasalow SD, Wang L, et al (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019-1031. doi: 10.1007/s00262-011-1172-6
60. Hamid O, Schmidt H, Nissan A, et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204. doi: 10.1186/1479-5876-9-204
61. Shahabi V, Whitney G, Hamid O, et al (2012) Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 61:733-737. doi: 10.1007/s00262-012-1227-3
62. la Fuente de H, Cibrián D, Sánchez-Madrid F (2012) Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett 586:2897-2905. doi: 10.1016/j.febslet.2012.07.032
63. Topalian SL, Hodi FS, Brahmer JR, et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454. doi: 10.1056/NEJMoa1200690
64. Brahmer JR, Tykodi SS, Chow LQM, et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465. doi: 10.1056/NEJMoa1200694
65. Hobo W, Novobrantseva TI, Fredrix H, et al (2012) Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. doi: 10.1007/s00262-012-1334-1
66. Seliger B, Quandt D (2012) The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 61:1327-1341. doi: 10.1007/s00262-012-1293-6
67. Yi KH, Chen L (2009) Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 229:145-151. doi: 10.1111/j.1600-065X.2009.00768.x
68. Textor S, Fiegler N, Arnold A, et al (2011) Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 71:5998-6009. doi: 10.1158/0008-5472.CAN-10-3211
69. Vetter CS, Groh V, thor Straten P, et al (2002) Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 118:600-605. doi: 10.1046/j.1523-1747.2002.01700.x
70. Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235:267-285. doi: 10.1111/j.0105-2896.2010.00893.x
71. Waldhauer I, Goehlsdorf D, Gieseke F, et al (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68:6368-6376. doi: 10.1158/0008-5472.CAN- 07-6768
72. Siemens DR, Hu N, Sheikhi AK, et al (2008) Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68:4746-4753. doi: 10.1158/0008-5472.CAN-08-0054
73. Barsoum IB, Hamilton TK, Li X, et al (2011) Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 71:7433-7441. doi: 10.1158/0008-5472.CAN-11-2104
74. Pruessmeyer J, Ludwig A (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 20:164-174. doi: 10.1016/j.semcdb.2008.09.005
75. Paschen A, Sucker A, Hill B, et al (2009) Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15:5208-5215. doi: 10.1158/1078-0432.CCR-09-0886
76. Benitez AC, Dai Z, Mann HH, et al (2011) Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Nat Acad Sci 108:4081-4086. doi: 10.1073/pnas.1018603108
77. Rak J (2013) Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol 4:21. doi: 10.3389/fphar.2013. 00021
78. Taylor DD, Doellgast GJ (1979) Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal Biochem 98:53-59
79. Taylor DD, Gercel-Taylor C (2011) Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 33:441-454. doi: 10.1007/s00281-010-0234-8
80. Filipazzi P, Bürdek M, Villa A, et al (2012) Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Sem Cancer Biol 22:342-349. doi: 10.1016/j.semcancer.2012.02.005
81. Huber V, Filipazzi P, Iero M, et al (2008) More insights into the immunosuppressive potential of tumor exosomes. J Transl Med 6:63. doi: 10.1186/1479-5876-6-63
82. van der Heyde HC, Gramaglia I, Combes V, et al (2011) Flow cytometric analysis of microparticles. Methods Mol Biol 699:337-354. doi: 10.1007/978-1-61737-950-5-16
83. Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41:245-251. doi: 10.1042/BST20120265
84. Xiang X, Poliakov A, Liu C, et al (2009) Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 124:2621-2633. doi: 10.1002/ijc.24249